Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Halobacterium salinarum DNA-directed RNA polymerase subunit B' (rpoB2), partial CSB-YP316230HTM
CSB-EP316230HTM
CSB-BP316230HTM
CSB-MP316230HTM
CSB-EP316230HTM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Halobacterium salinarum DNA-directed RNA polymerase subunit A' (rpoA2) CSB-YP316231HTM
CSB-EP316231HTM
CSB-BP316231HTM
CSB-MP316231HTM
CSB-EP316231HTM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Saccharomyces cerevisiae Enolase-related protein 2 (ERR2) CSB-YP316232SVG
CSB-EP316232SVG
CSB-BP316232SVG
CSB-MP316232SVG
CSB-EP316232SVG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Saccharomyces cerevisiae 60S ribosomal protein L43-A (RPL43A) CSB-YP316235SVG
CSB-EP316235SVG
CSB-BP316235SVG
CSB-MP316235SVG
CSB-EP316235SVG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Saccharomyces cerevisiae 40S ribosomal protein S23-B (RPS23B) CSB-YP316236SVG
CSB-EP316236SVG
CSB-BP316236SVG
CSB-MP316236SVG
CSB-EP316236SVG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Saccharomyces cerevisiae 40S ribosomal protein S4-A (RPS4A) CSB-YP316237SVG
CSB-EP316237SVG
CSB-BP316237SVG
CSB-MP316237SVG
CSB-EP316237SVG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Saccharomyces cerevisiae 40S ribosomal protein S8-B (RPS8B) CSB-YP316238SVG
CSB-EP316238SVG
CSB-BP316238SVG
CSB-MP316238SVG
CSB-EP316238SVG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Saccharomyces cerevisiae 40S ribosomal protein S11-A (RPS11A) CSB-YP316239SVG
CSB-EP316239SVG
CSB-BP316239SVG
CSB-MP316239SVG
CSB-EP316239SVG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Saccharomyces cerevisiae 40S ribosomal protein S18-A (RPS18A) CSB-YP316240SVG
CSB-EP316240SVG
CSB-BP316240SVG
CSB-MP316240SVG
CSB-EP316240SVG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Saccharomyces cerevisiae Transposon Ty1-PR2 Gag polyprotein (TY1A-PR2) CSB-YP316241SVG
CSB-EP316241SVG
CSB-BP316241SVG
CSB-MP316241SVG
CSB-EP316241SVG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Saccharomyces cerevisiae Transposon Ty1-DR5 Gag polyprotein (TY1A-DR5) CSB-YP316242SVG
CSB-EP316242SVG
CSB-BP316242SVG
CSB-MP316242SVG
CSB-EP316242SVG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Saccharomyces cerevisiae Transposon Ty1-PL Gag polyprotein (TY1A-PL) CSB-YP316243SVG
CSB-EP316243SVG
CSB-BP316243SVG
CSB-MP316243SVG
CSB-EP316243SVG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Saccharomyces cerevisiae 60S ribosomal protein L19-B (RPL19B) CSB-YP316244SVG
CSB-EP316244SVG
CSB-BP316244SVG
CSB-MP316244SVG
CSB-EP316244SVG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Saccharomyces cerevisiae Uncharacterized protein YHR214C-D (YHR214C-D), partial CSB-YP316245SVG1
CSB-EP316245SVG1
CSB-BP316245SVG1
CSB-MP316245SVG1
CSB-EP316245SVG1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Saccharomyces cerevisiae UPF0479 membrane protein YFL068W (YFL068W), partial CSB-YP316246SVG1
CSB-EP316246SVG1
CSB-BP316246SVG1
CSB-MP316246SVG1
CSB-EP316246SVG1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Saccharomyces cerevisiae Uncharacterized protein YLR154C-H (YLR154C-H) CSB-YP316247SVG
CSB-EP316247SVG
CSB-BP316247SVG
CSB-MP316247SVG
CSB-EP316247SVG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Saccharomyces cerevisiae Mating-type protein ALPHA1 (MATALPHA1) CSB-YP316248SVG
CSB-EP316248SVG
CSB-BP316248SVG
CSB-MP316248SVG
CSB-EP316248SVG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Saccharomyces cerevisiae Silenced mating-type protein A1 (HMRA1) CSB-YP316249SVG
CSB-EP316249SVG
CSB-BP316249SVG
CSB-MP316249SVG
CSB-EP316249SVG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Schizosaccharomyces pombe Mating-type M-specific polypeptide Mi (mat1-m) CSB-YP316250SXV
CSB-EP316250SXV
CSB-BP316250SXV
CSB-MP316250SXV
CSB-EP316250SXV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida albicans Serine/threonine-protein kinase CST20 (CST20), partial CSB-YP316252CZD
CSB-EP316252CZD
CSB-BP316252CZD
CSB-MP316252CZD
CSB-EP316252CZD-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>